Home » TRANSITION COMPLETES TARGET ENROLMENT IN DIABETES TRIAL
TRANSITION COMPLETES TARGET ENROLMENT IN DIABETES TRIAL
Transition Therapeutics has completed target enrolment for an exploratory Phase IIa clinical trial of its lead regenerative therapy, E1-I.N.T., in Type II diabetes patients. E1-I.N.T. is a short-course combination therapy aimed at stimulating the regeneration of the body's insulin-producing cells, called islet cells.
The exploratory clinical studies for E1-I.N.T. are randomized, double-blind, controlled trials to evaluate the safety, tolerability and efficacy of daily E1-I.N.T. treatments for 28 days with a six-month follow-up. The Type I diabetes clinical study examines 20 Type I diabetes patients (15 E1-I.N.T., 5 placebo) and the Type II diabetes clinical study examines 30 Type II diabetes patients (20 E1-I.N.T., 10 placebo).
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May